Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 6,959

Document Document Title
WO/2010/079809A1
Disclosed is a glycol compound which is useful as a starting material and an intermediate for a synthetic resin, an additive for a synthetic resin, a medicine, a cosmetic, a food additive, a surfactant, etc., further disclosed is a metho...  
WO/2010/080537A1
GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.  
WO/2010/079810A1
Disclosed is a glycol compound which is useful as a starting material and an intermediate body for a synthetic resin, an additive for a synthetic resin, a medicine, a cosmetic, a food additive, a surfactant, etc., further disclosed is a ...  
WO/2010/073512A1
A method for producing glycolide which comprises: a step (1) wherein a mixture comprising a glycolic acid oligomer and a high-boiling polar organic solvent is refluxed by heating under atmospheric or reduced pressure, while conducting th...  
WO/2010/058060A1
Compounds of formula (I), wherein X, Z, A, B, D, E, R1-R4 and m are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful as alpha2C antagonists.  
WO/2010/053275A2
The present invention relates to a high-yield method for preparing highly pure (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone using a metal salt of (2S,3S,5R)-2-hexyl-3,5-dihydroxyhexadecanoic acid as an intermediate.  
WO/2010/053275A3
The present invention relates to a high-yield method for preparing highly pure (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone using a metal salt of (2S,3S,5R)-2-hexyl-3,5-dihydroxyhexadecanoic acid as an intermediate.  
WO/2010/048715A1
The invention relates to gemini surfactants of formula IA wherein A is a core derived from an organic polyhydroxy compound; R1 and R2 are each independently a hydrophobic group; and R3 and R4 are each independently a surfactant head grou...  
WO/2010/046194A1
Cyclohexanedione compounds, which are suitable for use as herbicides.  
WO/2010/043584A1
The invention relates to the use of and mainly novel compounds of the formula (I) wherein the moieties are as defined in the description, which are useful as farnesyl pyrophosphate synthase modulators and e.g. in the treatment of prolife...  
WO/2010/043581A1
The invention relates to a method for producing cyclic carbonates by reacting a multivalent alcohol with a dialkyl carbonate in the presence of a heterogeneous catalyst, characterized in that the heterogeneous catalyst is a basic mixed o...  
WO/2010/042867A2
Disclosed are pyruvate kinase M2 activators, which are, bis sulfonamide piperazinyl compounds of Formula (I) and 2,4-disubstituted 4H-thieno[3,2-b]pyrrole-2-(substituted benzyl)pyridazin-3(2H)ones of Formula (II), wherein L and R1 to R16...  
WO/2010/041670A1
A novel alicyclic epoxy resin having no ester bond in each molecule, and a precursor of the alicyclic epoxy resin. The precursor is a diolefin compound represented by formula (1) (wherein each of the plurality of R's independently repres...  
WO/2010/042867A3
Disclosed are pyruvate kinase M2 activators, which are bis sulfonamide piperazinyl and piperidinyl compounds of Formula (I), 2,4-disubstituted 4H- thieno[3,2-c]pyrrole-2-(substituted benzyl)pyridazin-3(2H)-ones of Formula (II) and 6-(3,4...  
WO/2010/042600A2
Novel photo-activatable pro-therapeutic agents and methods for their synthesis and use are described. The photo-activatable pro-therapeutic agents are inactive pro-forms of compounds that can be activated in situ, for example, by providi...  
WO/2010/042600A3
Novel photo-activatable pro-therapeutic agents and methods for their synthesis and use are described. The photo-activatable pro-therapeutic agents are inactive pro-forms of compounds that can be activated in situ, for example, by providi...  
WO/2010/039256A1
A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or ...  
WO/2010/036884A1
The present disclosure relates to the preparation of acrylate, alkacrylate, allyl, and polycarbonate derivatives of hydroxy ketal esters, and uses thereof.  
WO/2010/023448A1
The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein; X1 is selected from a group consisting of CH2, C(=O), C(=NH), NC(=O), R1 is selected from the group consist...  
WO/2010/022966A8
The present invention relates to three variants for preparing a mixture of cyclic diesters derived from lactic acid and especially a racemate of dilactide. This can proceed, as desired, from the corresponding a-hydroxycarboxylic acids, t...  
WO/2010/022966A3
The present invention relates to three variants for preparing a mixture of cyclic diesters derived from lactic acid and especially a racemate of dilactide. This can proceed, as desired, from the corresponding a-hydroxycarboxylic acids, t...  
WO/2010/022966A2
The present invention relates to three variants for preparing a mixture of cyclic diesters derived from lactic acid and especially a racemate of dilactide. This can proceed, as desired, from the corresponding a-hydroxycarboxylic acids, t...  
WO/2010/021093A1
Provided are a novel asymmetric organic catalyst with which it is possible to realize a high optically-active yield when said catalyst is used in a small amount, and a method for producing a compound using the same. The asymmetric organi...  
WO/2010/020548A1
The present invention relates to a compound of the general formula (I) wherein R1/R2 are independently from each other lower alkyl, or form together with the N-atom to which they are attached a heterocyclic group, selected from pyrrolidi...  
WO/2010/020370A1
The invention relates to a method for storing and/or transporting intramolecular cyclic esters (lactones), in particular lactides.  
WO/2010/019911A3
The present invention includes compositions and methods for inhibiting kinase activity to protect against neurodegeneration including diseases such as Alzheimer's disease, Parkinson's disease, or Huntington's disease, and conditions such...  
WO/2010/018209A1
The present invention relates to a method of obtaining lactide using a solvent from the family of ethers, starting from a mixture that is in the liquid form comprising lactide, meso-lactide and other impurities.  
WO/2010/019911A2
The present invention includes compositions and methods for inhibiting kinase activity to protect against neurodegeneration including diseases such as Alzheimer's disease, Parkinson's disease, or Huntington's disease, and conditions such...  
WO/2010/017094A3
The present invention provides curcumin-derived near infrared (NIR) imaging probes. Upon interacting with amyloid β aggregates, these probes undergo a range of changes, qualifying them as "smart" probes. The inventors have demonstrated ...  
WO/2010/011548A1
The present invention is directed to novel substituted sulfamide derivatives, pharmaceutical compositions containing said derivatives and the use of said derivatives form in the treatment of anxiety and related disorders; bipolar depress...  
WO/2010/008776A2
A patch and sensor assembly for use in an EP mapping system has two portions: a reusable portion and a disposable portion. The reusable portion houses the biosensors used in magnetic based location and mapping systems and the electrical ...  
WO/2010/008776A3
A patch and sensor assembly for use in an EP mapping system has two portions: a reusable portion and a disposable portion. The reusable portion houses the biosensors used in magnetic based location and mapping systems and the electrical ...  
WO/2010/008776A9
A patch and sensor assembly for use in an EP mapping system has two portions: a reusable portion and a disposable portion. The reusable portion houses the biosensors used in magnetic based location and mapping systems and the electrical ...  
WO/2010/003299A1
An organic compound and preparation method thereof, particularly a flavor enhancer and preparation method thereof, are disclosed. Its chemical name is 4-isopropyl-5,5-dimethyl-m-dioxan-2-one. It is prepared by the following method: start...  
WO/2010/003624A3
Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, ...  
WO/2010/003624A2
Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, ...  
WO/2010/000193A1
The invention provides a process for preparing osemozotan and its pharmaceutically acceptable salts. The invention also provides an intermediate, (2R)-N-[3-(1,3- benzodioxol-5-yloxy)propyl]-1,4-benzodioxin-2-formamide, used in the proces...  
WO/2009/153886A1
A process for producing an α-hydroxy acid that is economically advantageous without the secondary production of a large volume of waste, having satisfactory quality as a polymer raw material. The process for producing an α-hydroxy acid...  
WO/2009/150248A1
The present invention relates to a compound of general formula (I) : and also to the pharmaceutically acceptable salts thereof, to the isomers or isomer mixtures thereof in all proportions, in particular to an enantiomer mixture, and esp...  
WO/2009/150963A1
Disclosed is a liquid crystal compound having general physical properties necessary for a compound, stability against heat, light or the like, a wide temperature range of a liquid crystal phase, a high clearing point, good compatibility ...  
WO/2009/150966A1
Disclosed is a liquid crystalline compound which is stable against heat, light or the like and has a nematic phase in a wide temperature range, while having a low viscosity, a large optical anisotropy, an adequate elastic constant K33, a...  
WO/2009/147632A3
The invention provides a method of preparing the stereoisomers of 1,11-diamino-6-aza- undecane-2,4,8,10-tetraol.  
WO/2009/143178A3
Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Hu...  
WO/2009/133107A1
The present invention relates to novel 1-(2,3-dihydro-1,4-benzodioxin-2-yl)- methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically as dopaminergic stabilizers. In other aspects the invention r...  
WO/2009/133110A1
The present invention relates to novel1-(4H-1,3-benzodioxin-2-yl)methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically asdopaminergic stabilizers. In other aspects the invention relates to the...  
WO/2009/133109A1
The present invention relates to novel 1-(2,3-dihydro-1,4-benzodioxin-2-yl)-methanamine derivatives, useful as modulators of dopamine neurotransmission, and more specifically as dopaminergic stabilizers. In other aspects the invention re...  
WO/2009/130422A3
The present invention relates to the use of acylthiourea or acylurea derivatives of formula (I) for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, an...  
WO/2009/129726A1
The present invention provides novel nitrones, their preparation and use. The novel compounds have the following formula: I The compounds of the present invention have strong antioxidative activity, and are thrombolytic. These compounds ...  
WO/2009/130422A2
The present invention relates to the use of acylthiourea or acylurea derivatives of formula (I) for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, an...  
WO/2009/128521A1
Disclosed are: a compound having an excellent inhibitory activity on cysteine protease; and a pharmaceutical agent for the treatment or prevention of a disease selected from the group consisting of osteoporosis, osteoarthrosis deformans,...  

Matches 201 - 250 out of 6,959